BJMO - volume 19, issue 1, january 2025
C. Fontaine MD, J. Collignon MD, P. Debruyne MD, PhD, L. Duck MD, E. Everaert MD, T. Feys MBA, MSc, C. Langenaeken MD, F. Lebrun MD, J. Mebis MD, E. Naert MD, P. Van Landuyt PharmD, S. Wuyts PharmD, C. van Marcke de Lummen MD, PhD, F. Vanryckeghem MD, V. Verschaeve MD, J. Klaskersky MD, PhD
Nausea and vomiting continue to be some of the more dreaded side effects of anticancer therapy. While advances in the prophylaxis of chemotherapy induced nausea vomiting (CINV), and guidance from international cancer societies have yielded important benefits for cancer patients, there remains an important need to further improve patient care. To address the need for a better CINV prophylaxis, and to respond to the introduction of new potentially emetogenic anticancer agents and the publication of new clinical trial data with anti-emetic agents, several international oncological societies have recently updated their guidelines for the prevention of CINV. The objective of this paper was to translate these new international recommendations to a Belgian context.
(BELG J MED ONCOL 2025;19(1):15–26)
Read moreBJMO - 2024, issue 3, may 2024
E. Naert MD
In this section of the BJMO, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjmo.be) and we will make sure to include it in the journal scan section of the next BJMO issue.
(Belg J Med Oncol 2024;18(3):15–8)
Read moreBJMO - volume 14, issue 7, november 2020
M. Rediti MD, K. Punie MD, E. de Azambuja MD, PhD, E. Naert MD, D. Taylor MD, FP. Duhoux MD, PhD, H. Denys MD, PhD, A. Awada MD, PhD, H. Wildiers MD, PhD, M. Ignatiadis MD, PhD
Chemotherapy has represented the main treatment option for patients with advanced triple-negative breast cancer for a long time. However, due to our better understanding of tumour biology, recent clinical trials led to a change in the treatment paradigm of this disease, identifying clinically relevant subgroups with different therapeutic options. Both clinical and biological factors have become relevant and need to be considered in the treatment decision algorithm of this heterogeneous disease.
(BELG J MED ONCOL 2020;14(7):333-38)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
